TR199902615T2 - Methods and compositions for modulating the response to corticosteroids. - Google Patents

Methods and compositions for modulating the response to corticosteroids.

Info

Publication number
TR199902615T2
TR199902615T2 TR1999/02615T TR9902615T TR199902615T2 TR 199902615 T2 TR199902615 T2 TR 199902615T2 TR 1999/02615 T TR1999/02615 T TR 1999/02615T TR 9902615 T TR9902615 T TR 9902615T TR 199902615 T2 TR199902615 T2 TR 199902615T2
Authority
TR
Turkey
Prior art keywords
agent
response
individual
corticosteroids
modulating
Prior art date
Application number
TR1999/02615T
Other languages
Turkish (tr)
Inventor
Sekut Les
Carter Adam
Ghayur Tariq
Banerjee Subhashis
E.Tracey Daniel
Original Assignee
Basf Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/820,692 external-priority patent/US6054487A/en
Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft
Publication of TR199902615T2 publication Critical patent/TR199902615T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Bir bireyde kortikosteroidlere verilen cevabin modüle edilmesine yönelik metod ortaya konulmaktadir. Bu bulusun metodunda, bireyde IFN-y üretimini regüle eden bir hedefi antagonize eden bie ajan bireye bir kortikosteroid ile kombinasyon halinde uygulanir ve bireye sadece bir kortikosteroidin uygulanmasi durumuna kiyasla-bireyin kortikosteroide cevabi modüle edilir. Bir tecessümde, ajan bir IL-18 antagonistidir. Bir baska tecessümde, ajan bir interlökin-12 (IL-12) antagonistidir. Bir diger tecessümde, ajan bir NK hücresi antagonistidir. Tercih edilen bir tecessümde, ajan bir kaspaz familyasi proteazinin bir inhibitörüdür, ve tercihen de bir ICE inhibitörüdür. tercih edilen bir baska tecessümde, ajan bir IL-12 monoklonal antikorudur.The method for modulating the response to corticosteroids in an individual is introduced. In the method of this invention, an agent that antagonizes a target that regulates IFN-üretim production in the individual is administered to the individual in combination with a corticosteroid, and the individual's response to the corticosteroid is modulated compared to the administration of only one corticosteroid. In one embodiment, the agent is an IL-18 antagonist. In another embodiment, the agent is an interleukin-12 (IL-12) antagonist. In another embodiment, the agent is an NK cell antagonist. In a preferred embodiment, the agent is an inhibitor of a caspase family protease, and preferably an ICE inhibitor. In another preferred embodiment, the agent is an IL-12 monoclonal antibody.

TR1999/02615T 1997-03-18 1998-03-12 Methods and compositions for modulating the response to corticosteroids. TR199902615T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/820,692 US6054487A (en) 1997-03-18 1997-03-18 Methods and compositions for modulating responsiveness to corticosteroids
US1634698A 1998-01-30 1998-01-30

Publications (1)

Publication Number Publication Date
TR199902615T2 true TR199902615T2 (en) 2000-03-21

Family

ID=26688484

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/02615T TR199902615T2 (en) 1997-03-18 1998-03-12 Methods and compositions for modulating the response to corticosteroids.

Country Status (20)

Country Link
EP (1) EP0998300A1 (en)
JP (1) JP2002504091A (en)
KR (1) KR20000076420A (en)
CN (1) CN1269722A (en)
AU (1) AU734756B2 (en)
BG (1) BG103808A (en)
BR (1) BR9810409A (en)
CA (1) CA2282845A1 (en)
DE (1) DE998300T1 (en)
ES (1) ES2146192T1 (en)
HU (1) HUP0104439A3 (en)
ID (1) ID22975A (en)
IL (1) IL131815A0 (en)
NO (1) NO994506L (en)
NZ (1) NZ337769A (en)
PL (1) PL336464A1 (en)
SI (1) SI20110A (en)
SK (1) SK122199A3 (en)
TR (1) TR199902615T2 (en)
WO (1) WO1998041232A2 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US6706264B1 (en) 1994-03-14 2004-03-16 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
AR015966A1 (en) * 1997-10-17 2001-05-30 Smithkline Beecham Corp USE OF A PDE4 INHIBITOR COMPOUND FOR THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR PRURITE TREATMENT
EP1516630A3 (en) * 1997-10-31 2006-05-03 Wyeth Use of anti-il-12 antibodies in transplantation rejection
AU744302B2 (en) * 1997-10-31 2002-02-21 Beth Israel Deaconess Medical Center Use of anti-IL-12 antibodies in transplantation rejection
WO1999025737A1 (en) * 1997-11-19 1999-05-27 Tanox Pharma B.V. Compositions and methods for treatment of autoimmune diseases, using a monoclonal antibody to the interleukin-12 beta2-chain
US6153591A (en) * 1998-03-16 2000-11-28 Cytovia, Inc. Dipeptide caspase inhibitors and the use thereof
CA2355345A1 (en) * 1998-11-27 2001-06-28 Technion Research & Development Foundation Ltd. Interferon gamma inducing factor based vaccine and use of same for protective immunity against multiple sclerosis
US6410824B1 (en) * 1998-12-09 2002-06-25 Protein Design Labs, Inc. Animal model for psoriasis for the prevention and treatment of psoriasis in humans
CN1346344A (en) 1999-03-16 2002-04-24 西托维亚公司 Substituted 2-aminobenzamide caspase ihibitors and the use thereof
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
DE19915465A1 (en) * 1999-04-06 2000-10-19 Apotech Res & Dev Ltd Use of a caspase inhibitor to inhibit cell proliferation and use of one or more caspase inhibitors to treat diseases based on lymphocyte hyperproliferation or to suppress an immune response by lymphocytes
EP1177168B1 (en) 1999-04-09 2007-05-30 Cytovia, Inc. Caspase inhibitors and the use thereof
IL131047A0 (en) * 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
DE60040397D1 (en) 1999-08-27 2008-11-13 Cytovia Inc SUBSTITUTED ALPHA HYDROXY ACIDS AS CASPASE INHIBITORS AND THEIR USE
AU7127600A (en) * 1999-09-17 2001-04-17 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
KR20110032012A (en) 2000-02-10 2011-03-29 아보트 러보러터리즈 Antibodies that bind human interleukin-18 and methods of making and using
WO2001093909A2 (en) * 2000-06-06 2001-12-13 Glaxo Group Limited Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor
WO2001097815A2 (en) * 2000-06-22 2001-12-27 Willy Ben Moussa Ben Mohammed Use of glucocorticosteroids for producing a medicament to treat oligotrichia
US20020025317A1 (en) * 2000-07-20 2002-02-28 Schering Ag Bispecific monoclonal antibodies to IL-12 and IL-18
AU2000270300A1 (en) * 2000-09-13 2002-03-26 Isis Innovation Limited Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
EP1188438A1 (en) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
EP1199074A1 (en) * 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
EA010180B1 (en) * 2001-01-29 2008-06-30 Лаборатуар Сероно Са Use of il-18 inhibitors in the preparation of a medicament for the treatment and/or prevention of cardiomyopathy
DK1425028T3 (en) * 2001-05-16 2010-03-01 Yeda Res & Dev Use of IL-18 inhibitors to treat or prevent sepsis
ES2907826T3 (en) 2001-06-26 2022-04-26 Amgen Inc Antibodies to OPGL
ATE502642T1 (en) * 2001-10-05 2011-04-15 Zalicus Inc COMBINATIONS FOR THE TREATMENT OF IMMUNO-INFLAMMATORY DISEASES
JP2003342196A (en) * 2002-05-31 2003-12-03 Mukku:Kk Composition for intravenous injection, method of production for the same and its preparation
AR041386A1 (en) * 2002-09-24 2005-05-18 Combinatorx Inc METHODS AND REAGENTS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH INCREASED LEVELS OF PROINFLAMATORY CYTOKINS
AU2003263717A1 (en) * 2002-09-25 2004-04-19 Astrazeneca Ab A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
WO2004067006A1 (en) * 2003-01-27 2004-08-12 Pharmacia Corporation Combination of a pde iv inhibitor and a tnf-alpha antagonist
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
WO2005110450A1 (en) * 2004-05-17 2005-11-24 Keio University Medicinal composition and therapeutic method
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AU2005264453B2 (en) 2004-07-16 2011-07-14 Atsuo Sekiyama IL-18 receptor antagonist and pharmaceutical composition containing the antagonist
CA2584169A1 (en) * 2004-10-13 2006-04-20 Kyowa Hakko Kogyo Co., Ltd. Remedies/preventives for chronic skin disease
JP4778053B2 (en) 2005-07-14 2011-09-21 リセラ，インコーポレイテッド Extended release lipolytic formulation for topical adipose tissue treatment
CA2666612C (en) * 2006-10-17 2012-11-27 Lipothera, Inc. Methods, compositions, and formulations for the treatment of thyroid eye disease
RU2475265C2 (en) 2007-01-16 2013-02-20 Эбботт Лэборетриз Methods of treating psoriasis
KR20100014674A (en) 2007-03-29 2010-02-10 아보트 러보러터리즈 Crystalline anti-human il-12 antibodies
US8178092B2 (en) 2008-03-18 2012-05-15 Abbott Laboratories Methods of treating psoriasis by administration of antibodies to the p40 subunit of IL-12 and/or IL-23
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
SG190878A1 (en) 2010-11-24 2013-07-31 Lithera Inc Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
WO2015063669A1 (en) 2013-10-30 2015-05-07 Wockhardt Limited Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof
US12102622B2 (en) 2021-02-10 2024-10-01 Iolyx Therapeutics, Inc. Methods for ophthalmic delivery of roflumilast
EP4405048A1 (en) * 2021-09-22 2024-07-31 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320125A (en) * 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
NZ235222A (en) * 1989-09-08 1992-11-25 Glaxo Group Ltd Inhalatory composition comprising salmeterol and beclomethasone dipropionate
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
MX9304585A (en) * 1992-07-31 1994-03-31 Glaxo Group Ltd PHARMACEUTICAL FORMULATION IN AEROSOL, CAN SUITABLE TO RELEASE THE FORMULATION AND INHALER OF DOSE DOSE THAT COMPRISES THE CAN.
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
CN1186473A (en) * 1995-04-14 1998-07-01 葛兰素惠尔康公司 Metered dose inhaler for beclomethasone dipropionate

Also Published As

Publication number Publication date
EP0998300A1 (en) 2000-05-10
NO994506L (en) 1999-11-17
DE998300T1 (en) 2001-03-01
JP2002504091A (en) 2002-02-05
BR9810409A (en) 2000-08-22
WO1998041232A3 (en) 2000-10-05
SI20110A (en) 2000-06-30
AU6760498A (en) 1998-10-12
HUP0104439A3 (en) 2002-08-28
WO1998041232A2 (en) 1998-09-24
IL131815A0 (en) 2001-03-19
CA2282845A1 (en) 1998-09-24
SK122199A3 (en) 2000-12-11
BG103808A (en) 2000-07-31
NO994506D0 (en) 1999-09-17
ES2146192T1 (en) 2000-08-01
AU734756B2 (en) 2001-06-21
NZ337769A (en) 2002-09-27
PL336464A1 (en) 2000-06-19
ID22975A (en) 1999-12-23
HUP0104439A2 (en) 2002-04-29
CN1269722A (en) 2000-10-11
KR20000076420A (en) 2000-12-26

Similar Documents

Publication Publication Date Title
TR199902615T2 (en) Methods and compositions for modulating the response to corticosteroids.
WO2001019373A3 (en) Methods and compositions for modulating responsiveness to corticosteroids
MX9602818A (en) A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS.
ATE407696T1 (en) PREVENTIVE OR CURE FOR THE TREATMENT OF MULTIPLE SCLERosis, CONTAINING ANTAGONISTIC ANTI-IL6 RECEPTOR ANTIBODIES AS THE ACTIVE INGREDIENTS
ATE301994T1 (en) METHOD FOR RELIEVING PAIN THROUGH A COMBINATION OF TRAMADOL AND AN NMDA ANTAGONIST
DK1061929T3 (en) Pharmaceutical composition based on synthetic natural progesterone and oestradiol and method of preparation thereof
ATE389019T1 (en) INTERLEUKIN-12 P40 AND INTERLEUKIN-B30. COMBINATIONS OF THESE. ANTIBODY. USES IN PHARMACEUTICAL COMPOSITIONS
DE69840025D1 (en) ASSOCIATED ANSWERS
DK0873340T3 (en) Heterocyclic substituted cyclopentane compounds
EP2336187A3 (en) Compositions and methods of monoclonal and polyclonal antibodies specific for T cell subpopulations
ATE350060T1 (en) AGENTS FOR PREVENTING OR TREATING PANCREATITIS WHICH CONTAIN ANTI-IL-6 RECEPTOR ANTIBODIES AS THE ACTIVE COMPONENT
PT944396E (en) COMPOSITIONS AND PROCESSES FOR IMPROVING GASTROINTESTINAL OPERATION
TR200001218T2 (en) Substituted carboxamidothiazoles, their manufacture and pharmaceutical compositions containing them.
PL309353A1 (en) Novel peptides, method of obtaining them and their application
Martinelli et al. Utility of embolization or chemoembolization as second‐line treatment in patients with advanced or recurrent colorectal carcinoma
UA37259C2 (en) Active substance for pharmaceutical compositions intended for treatment of dysfunctional metrorrhagia
GB2403593A (en) Implanted hidden interconnections in a semiconductor device for preventing reverse engineering
MXPA03003682A (en) Method of determining global coagulability and hemostatic potential.
ATE332919T1 (en) INHIBITORS OF PHOSPHOSERINE AND PHOSPHOTHREONEN-SPECIFIC ISOMERASES
BG103016A (en) Polypeptides capable of forming antigen-binding structures of specificity to rhesus d antigens, their encoding dna and method for their prparation and application
ES2171589T3 (en) SOLID PHARMACEUTICAL COMPOSITIONS ANHYDRA FOR VAGINAL USE.
ES2088128T3 (en) ACAT INHIBITOR AMINOSULFONILUREAS.
ATE205074T1 (en) MAKEUP SET WITH FILM-FORMING COMPOSITIONS
AU1023497A (en) Tissue factor - kunitz domain fusion proteins as factor viia inhibitors
ES2164822T3 (en) BIOSENSORS SENSITIVE TO THE MASS.